CL2017001478A1 - Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un inhibidor de factor de crecimiento epidérmico (egfr) - Google Patents

Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un inhibidor de factor de crecimiento epidérmico (egfr)

Info

Publication number
CL2017001478A1
CL2017001478A1 CL2017001478A CL2017001478A CL2017001478A1 CL 2017001478 A1 CL2017001478 A1 CL 2017001478A1 CL 2017001478 A CL2017001478 A CL 2017001478A CL 2017001478 A CL2017001478 A CL 2017001478A CL 2017001478 A1 CL2017001478 A1 CL 2017001478A1
Authority
CL
Chile
Prior art keywords
dihydro
oxo
combination
egfr
growth factor
Prior art date
Application number
CL2017001478A
Other languages
English (en)
Inventor
Friedheim Bladt
Hamim Manja Friese
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52133768&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001478(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CL2017001478A1 publication Critical patent/CL2017001478A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>UNA COMPOSICIÓN FARMACÉUTICA DE 3-(1 -{3-[5-(1 -METIL-PIPERIDIN-4-ILMETOXI)-PIRIMIDIN-2-IL]-BENCIL}-6-OXO-1 ,6-DIHIDRO-PIRIDAZIN-3-II)- BENZONITRILO O UNA SAL Y/O SOLVATO FARMACÉUTICAMENTE ACEPTABLE DEL MISMO EN COMBINACIÓN CON N-[3-[[2-[4-(4-ACETILPIPERAZIN-1-II)-2- METOXI-ANILINO]-5-(TRIFLUOROMETIL)PIRIMIDIN-4-IL]AMINO]FENIL]PROP-2-ENAMIDA.</p>
CL2017001478A 2014-12-12 2017-06-09 Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un inhibidor de factor de crecimiento epidérmico (egfr) CL2017001478A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14004200 2014-12-12

Publications (1)

Publication Number Publication Date
CL2017001478A1 true CL2017001478A1 (es) 2018-01-05

Family

ID=52133768

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001478A CL2017001478A1 (es) 2014-12-12 2017-06-09 Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un inhibidor de factor de crecimiento epidérmico (egfr)

Country Status (17)

Country Link
US (2) US10532052B2 (es)
EP (1) EP3229806A1 (es)
JP (1) JP2017537939A (es)
KR (1) KR20170090499A (es)
CN (1) CN106999493A (es)
AU (1) AU2015360005A1 (es)
BR (1) BR112017012136A2 (es)
CA (1) CA2970391A1 (es)
CL (1) CL2017001478A1 (es)
IL (1) IL252752A0 (es)
MX (1) MX2017007372A (es)
PH (1) PH12017500718A1 (es)
RU (1) RU2017124612A (es)
SG (1) SG11201704767YA (es)
UA (1) UA120108C2 (es)
WO (1) WO2016091346A1 (es)
ZA (1) ZA201704654B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10196363B2 (en) 2014-12-12 2019-02-05 Japan Tobacco Inc. Dihydropyrimidin-2-one compounds and medical use thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3087994A1 (en) 2018-02-28 2019-09-06 Japan Tobacco Inc. 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
US11455294B2 (en) * 2019-10-18 2022-09-27 Sap Se Information lifecycle management notification framework

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090155247A1 (en) 2005-02-18 2009-06-18 Ashkenazi Avi J Methods of Using Death Receptor Agonists and EGFR Inhibitors
US20060188498A1 (en) 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
CA2738583A1 (en) * 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
MX350894B (es) 2009-01-08 2017-09-22 Merck Patent Gmbh * Nuevas formas polimorficas de sal de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-bencil} -6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo y sus procesos de preparacion.
KR101954593B1 (ko) 2010-11-01 2019-03-06 셀젠 카르 엘엘씨 헤테로사이클릭 화합물 및 이의 용도
BR112014022789B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
BR112014022266A2 (pt) 2012-03-19 2021-09-08 Merck Patent Gmbh Combinação de um derivado de 6-oxo-1,6-di-hidro-piridazina tendo atividade anticâncer com outros compostos antitumor
CN110507654A (zh) * 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
US20150297594A1 (en) 2012-10-11 2015-10-22 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a MEK inhibitor
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10196363B2 (en) 2014-12-12 2019-02-05 Japan Tobacco Inc. Dihydropyrimidin-2-one compounds and medical use thereof

Also Published As

Publication number Publication date
EP3229806A1 (en) 2017-10-18
JP2017537939A (ja) 2017-12-21
RU2017124612A3 (es) 2019-06-05
WO2016091346A1 (en) 2016-06-16
MX2017007372A (es) 2017-11-06
AU2015360005A1 (en) 2017-07-27
US10532052B2 (en) 2020-01-14
CN106999493A (zh) 2017-08-01
UA120108C2 (uk) 2019-10-10
RU2017124612A (ru) 2019-01-14
KR20170090499A (ko) 2017-08-07
CA2970391A1 (en) 2016-06-16
BR112017012136A2 (pt) 2018-01-02
PH12017500718A1 (en) 2017-10-09
US20170319581A1 (en) 2017-11-09
ZA201704654B (en) 2019-08-28
SG11201704767YA (en) 2017-07-28
IL252752A0 (en) 2017-08-31
US20190388423A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
MX2018013983A (es) Inhibidores g12c de kras.
CY1123295T1 (el) Κρυσταλλικες μορφες της 5-χλωρο-ν4-[-2-(διμεθυλοφωσφορυλο) φαινυλο]-ν2-{2-μεθοξυ-4-[4-(4-μεθυλοπιπεραζιν-1-υλο)πιπεριδιν- 1-υλο]πυριμιδινο-2,4-διαμινης
DK3154959T3 (da) 1-((3s,4r)-4-(3-fluorphenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urinstof som en trka-kinaseinhibitor
MD3464265T2 (ro) Polimorfi de N-[(3-fluoro-4-metoxipiridin-2-il)metil]-3-(metoximetil)-1-({4-[2-oxopiridin-1-il)metil]fenil}metil)pirazol-4-carboxamidă ca inhibitori de kalicreină
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CR20130649A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
CL2016000405A1 (es) Uso de bardoxolón metilo o análogos del mismo para el tratamiento y/o prevención de la disfunción endotelial.
UA122520C2 (uk) Кристалічна форма 2-[4-(4-хлорфенокси)-2-(трифторметил)феніл]-1-(1,2,4-триазол-1-іл)пропан-2-олу, агрохімічна композиція, застосування та спосіб боротьби зі шкідливими грибами
EA201591420A1 (ru) Гетероарильные соединения и их применение
UY34161A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida, sus usos, y composiciones que la contienen
CL2016002495A1 (es) Derivados de piridina macrocíclicos .
CL2016001172A1 (es) Nuevos inhibidores de dgat2.
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
EA201692474A1 (ru) Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2
CL2017001478A1 (es) Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un inhibidor de factor de crecimiento epidérmico (egfr)
CL2017001477A1 (es) Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un derivado de quinazolina
EA201791716A1 (ru) Фармацевтический состав
MX2023001805A (es) Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida.
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
DK3408260T3 (da) Krystallinsk (2s,4r)-5-(5&#39;-chlor-2-fluor-[1,1&#39;-biphenyl]-4-yl)-2-(ethoxy¬methyl)-4-(3-hydroxyisoxazol-5-carboxamido)-2-methylpentansyre og anvendelser deraf
AR092991A1 (es) Combinacion de un derivado de a 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de proteinquinasa activada por mitogenos (mek)
PH12016500948A1 (en) Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib
AR101523A1 (es) Compuestos para el tratamiento de condiciones asociadas con la actividad de dgat1
GB2543709A (en) Pharmaceutical agent
DK3585776T3 (da) 5-(pyrimidin-4-yl)-2-(pyrrolidin-1-yl)nicotinonitril-forbindelser som ikke, tbk1 og/eller sik2 kinaseinhibitorer